In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Blueprint Medicines Corp (NASDAQ: BPMC) was $114.05 for the day, down -0.24% from the previous closing price of $114.32. In other words, the price has decreased by -$0.24 from its previous closing price. On the day, 1.3 million shares were traded. BPMC stock price reached its highest trading level at $116.0 during the session, while it also had its lowest trading level at $112.7304.
Ratios:
Our analysis of BPMC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.32. In the meantime, Its Debt-to-Equity ratio is 2.34 whereas as Long-Term Debt/Eq ratio is at 1.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on November 14, 2024, initiated with a Overweight rating and assigned the stock a target price of $126.
On October 24, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $88.
On May 14, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $140.Stephens initiated its Overweight rating on May 14, 2024, with a $140 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 21 ’25 when Haviland Kate sold 1,446 shares for $110.24 per share. The transaction valued at 159,407 led to the insider holds 149,378 shares of the business.
Rossi Christina sold 2,274 shares of BPMC for $250,455 on Jan 21 ’25. The CHIEF OPERATING OFFICER now owns 67,109 shares after completing the transaction at $110.14 per share. On Jan 21 ’25, another insider, Albers Jeffrey W., who serves as the Director of the company, sold 15,161 shares for $109.53 each. As a result, the insider received 1,660,511 and left with 152,396 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 7245117440 and an Enterprise Value of 7260803584. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.68 while its Price-to-Book (P/B) ratio in mrq is 23.11. Its current Enterprise Value per Revenue stands at 16.714 whereas that against EBITDA is -27.699.
Stock Price History:
The Beta on a monthly basis for BPMC is 0.62, which has changed by 0.4365418 over the last 52 weeks, in comparison to a change of 0.21794415 over the same period for the S&P500. Over the past 52 weeks, BPMC has reached a high of $121.90, while it has fallen to a 52-week low of $72.24. The 50-Day Moving Average of the stock is 17.28%, while the 200-Day Moving Average is calculated to be 16.48%.
Shares Statistics:
BPMC traded an average of 735.62K shares per day over the past three months and 848400 shares per day over the past ten days. A total of 63.45M shares are outstanding, with a floating share count of 62.28M. Insiders hold about 1.96% of the company’s shares, while institutions hold 103.94% stake in the company. Shares short for BPMC as of 1736899200 were 5141950 with a Short Ratio of 6.99, compared to 1734048000 on 4527782. Therefore, it implies a Short% of Shares Outstanding of 5141950 and a Short% of Float of 9.120000000000001.
